Need help finding what you are looking for?
Contact Us
PUBLISHER: BCC Research | PRODUCT CODE: 2126246
PUBLISHER: BCC Research | PRODUCT CODE: 2126246
The U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
PUBLISHED:
PAGES: 107 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
The U.S. market for biodefense-related rapid pathogen identification and treatments is expected to grow from $8.4 billion in 2026 and is projected to reach $12.1 billion by the end of 2031, at a compound annual growth rate (CAGR) of 7.5% during the forecast period of 2026 to 2031.
Report Scope
This report examines the current and future market potential of the U.S. market for biodefense-related rapid pathogen identification and treatments. It offers a detailed analysis of the competitive environment, regulatory scenario, technological development, drivers and restraints, and identifies opportunities and trends in market growth.
The report provides an overview of the U.S. market for biodefense-related rapid pathogen identification and treatments and analyzes market trends. It includes global revenue ($ million) for the base year 2025 and estimated data for the forecast period 2026 to 2031. Based on type, the market is segmented into detection devices, sensors, and therapeutics. The detection devices segment is further segmented based on testing method and device type. The report also focuses on segmentation based on application and end user. The application segmentation includes detection and diagnosis, prevention, and treatment.
By end user, the market is segmented into academic and research institutes, government and defense agencies, hospitals, and pharma and biotechnology companies. The report focuses on the major emerging technologies that affect the market and vendor landscape. It also has a dedicated section of company profiles that covers details of leading key companies.
Report Includes
- 28 data tables and 51 additional tables
- An overview and analysis of the U.S. market for biodefense-related rapid pathogen identification and treatments
- Analyses of market trends, with revenue data for 2023-2025, estimates for 2026, and forecasts through 2031
- Market segmentation analysis by type, including detection devices and sensors
- Market breakdown by application, including detection and diagnosis, prevention, and treatment
- Market analysis by end user, including academic and research institutes, government and defense agencies, hospitals, and pharma and biotechnology companies
- Facts and figures related to market dynamics, including key drivers, restraints, and opportunities
- Insights derived from Porter's Five Forces analysis
- Discussion of emerging technologies, recent developments, and patent activity
- Analysis of the competitive landscape, including industry structure and company share analysis
- Company profiles of the leading players, including Thermo Fisher Scientific Inc., Biomerieux, F. Hoffmann-La Roche Ltd., Abbott, and OraSure Technologies Inc.
Product Code: BIO145C
Table of Contents
Chapter 1 Executive Summary
- Market Outlook
- Scope of Report
- Market Summary
- Market Dynamics and Growth Factors
- Emerging Technologies
- Segmental Analysis
- Conclusion
Chapter 2 Market Overview
- Overview
- Delivery and Detection
- Methods of Dissemination
- Rapid Identification Products
- Treatment
- Vaccines
- Antibiotics
- Antimicrobial Resistance
- Porter's Five Forces Analysis
- Threat of New Entrants (Moderate)
- Bargaining Power of Suppliers (Low to Moderate)
- Bargaining Power of Buyers (High)
- Threat of Substitute Products (Low)
- Industry Rivalry (High)
- Macroeconomic Factor Analysis
- U.S. Tariffs
- Increasing Healthcare Expenditures
- Geopolitical Factors
Chapter 3 Market Dynamics
- Market Dynamics
- Market Drivers
- High Federal Funding and Biodefense Investments
- Increasing Need for Infectious Disease Detection and Outbreak Surveillance
- Increased Emergency Use Authorizations and Product Approvals
- Market Restraints
- High Equipment and Testing Costs
- Lack of Awareness and Underdiagnosis of Infectious Conditions
- Regulatory Barriers
- Market Opportunities
- Pathogen-Agnostic Detection Approaches
- Point-of-Care Testing
- Self-Testing Kits for Pathogen Detection
Chapter 4 Regulatory Landscape
- U.S. Regulatory Aspects of Pathogen Identification Devices
- U.S. Regulatory Aspects of Therapeutics for Pathogenic Conditions
Chapter 5 Emerging Technologies
- Key Takeaways
- Emerging Technologies
- Multiplex PCR Syndromic Testing
- AI-Based Biodefense Surveillance
- Messenger RNA (mRNA) Vaccines
- CRISPR-Based Diagnostics
- Lab-on-a-Chip Systems for Public Health Monitoring
Chapter 6 Market Segmentation Analysis
- Segmentation Breakdown
- Market Analysis by Type
- Key Takeaways
- Detection Devices
- Sensors
- Therapeutics
- Market Analysis by Application
- Key Takeaways
- Detection and Diagnosis
- Prevention
- Treatment
- Market Analysis by End User
- Key Takeaways
- Government and Defense Agencies
- Hospitals
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutions
Chapter 7 Competitive Intelligence
- Key Takeaways
- Industry Structure
- Competitive Analysis of U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
- Strategic Analysis
Chapter 8 Appendix
- Methodology
- Sources
- Abbreviations
- Company Profiles
- ABBOTT
- AGILENT TECHNOLOGIES INC.
- BD
- BIOMERIEUX
- BIO-RAD LABORATORIES INC.
- CEPHEID
- CHARLES RIVER LABORATORIES
- F. HOFFMANN-LA ROCHE LTD.
- GENSCRIPT
- GSK PLC
- ILLUMINA INC.
- JOHNSON & JOHNSON
- ORASURE TECHNOLOGIES INC.
- QIAGEN
- REVVITY
- THERMO FISHER SCIENTIFIC INC.
- Emerging Startups/Market Disruptors
Product Code: BIO145C
List of Tables
- Summary Table : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, Through 2031
- Table 1 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, Through 2031
- Table 2 : U.S. Market for Biodefense-Related Rapid Pathogen Detection Devices, by Testing Method, Through 2031
- Table 3 : U.S. Market for Biodefense-Related Rapid Pathogen Detection Devices, by Device Type, Through 2031
- Table 4 : Characteristics of Biosensors
- Table 5 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by Application, Through 2031
- Table 6 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Detection and Diagnosis, Through 2031
- Table 7 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Prevention, Through 2031
- Table 8 : U.S. Market for Biodefense-Related Rapid Pathogen Identification for Treatments, Through 2031
- Table 9 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, by End User, Through 2031
- Table 10 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Government and Defense Agencies, Through 2031
- Table 11 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Hospitals, Through 2031
- Table 12 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Pharmaceutical and Biotechnology Companies, Through 2031
- Table 13 : U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments for Academic and Research Institutes, Through 2031
- Table 14 : Competitive Ranking of U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, 2025
- Table 15 : Recent Developments in the U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments, 2024-2025
- Table 16 : Report Information Sources
- Table 17 : Abbreviations Used in This Report
- Table 18 : Abbott: Company Snapshot
- Table 19 : Abbott: Financial Performance, FY 2024 and 2025
- Table 20 : Abbott: Product Portfolio
- Table 21 : Abbott: News/Key Developments, 2024
- Table 22 : Agilent Technologies Inc.: Company Snapshot
- Table 23 : Agilent Technologies Inc.: Financial Performance, FY 2024 and 2025
- Table 24 : Agilent Technologies Inc.: Product Portfolio
- Table 25 : Agilent Technologies Inc.: News/Key Developments, 2024
- Table 26 : BD: Company Snapshot
- Table 27 : BD: Financial Performance, FY 2024 and 2025
- Table 28 : BD: Product Portfolio
- Table 29 : BD: News/Key Developments, 2025
- Table 30 : Biomerieux: Company Snapshot
- Table 31 : Biomerieux: Financial Performance, FY 2024 and 2025
- Table 32 : Biomerieux: Product Portfolio
- Table 33 : Biomerieux: News/Key Developments, 2024
- Table 34 : Bio-Rad Laboratories Inc.: Company Snapshot
- Table 35 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2024 and 2025
- Table 36 : Bio-Rad Laboratories Inc.: Product Portfolio
- Table 37 : Bio-Rad Laboratories Inc.: News/Key Developments, 2025
- Table 38 : Cepheid: Company Snapshot
- Table 39 : Cepheid: Product Portfolio
- Table 40 : Cepheid: News/Key Developments, 2024-2025
- Table 41 : Charles River Laboratories: Company Snapshot
- Table 42 : Charles River Laboratories: Financial Performance, FY 2024 and 2025
- Table 43 : Charles River Laboratories: Product Portfolio
- Table 44 : F. Hoffmann-La Roche Ltd.: Company Snapshot
- Table 45 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2024 and 2025
- Table 46 : F. Hoffmann-La Roche Ltd.: Product Portfolio
- Table 47 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024-2025
- Table 48 : Genscript: Company Snapshot
- Table 49 : Genscript: Financial Performance, FY 2024 and 2025
- Table 50 : Genscript: Product Portfolio
- Table 51 : Genscript: News/Key Developments, 2024
- Table 52 : GSK plc: Company Snapshot
- Table 53 : GSK plc: Financial Performance, FY 2024 and 2025
- Table 54 : GSK plc: Product Portfolio
- Table 55 : GSK plc: News/Key Developments, 2024
- Table 56 : Illumina Inc.: Company Snapshot
- Table 57 : Illumina Inc.: Financial Performance, FY 2024 and 2025
- Table 58 : Illumina Inc.: Product Portfolio
- Table 59 : Illumina Inc.: News/Key Developments, 2025
- Table 60 : Johnson & Johnson: Company Snapshot
- Table 61 : Johnson & Johnson: Financial Performance, FY 2024 and 2025
- Table 62 : Johnson & Johnson: Product Portfolio
- Table 63 : Johnson & Johnson: News/Key Developments, 2024
- Table 64 : OraSure Technologies Inc.: Company Snapshot
- Table 65 : OraSure Technologies Inc.: Financial Performance, FY 2024 and 2025
- Table 66 : OraSure Technologies Inc.: Product Portfolio
- Table 67 : OraSure Technologies Inc.: News/Key Developments, 2024-2025
- Table 68 : Qiagen: Company Snapshot
- Table 69 : Qiagen: Financial Performance, FY 2024 and 2025
- Table 70 : Qiagen: Product Portfolio
- Table 71 : Qiagen: News/Key Developments, 2025
- Table 72 : Revvity: Company Snapshot
- Table 73 : Revvity: Financial Performance, FY 2024 and 2025
- Table 74 : Revvity: Product Portfolio
- Table 75 : Thermo Fisher Scientific Inc.: Company Snapshot
- Table 76 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2024 and 2025
- Table 77 : Thermo Fisher Scientific Inc.: Product Portfolio
- Table 78 : List of a Few Emerging Startups
List of Figures
- Summary Figure : U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, 2025
- Figure 1 : Porter's Five Forces Analysis: U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
- Figure 2 : Market Dynamics of U.S. Biodefense-Related Rapid Pathogen Identification and Treatments
- Figure 3 : Emerging Technologies in U.S. Market for Biodefense-Related Rapid Pathogen Identification and Treatments
- Figure 4 : U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by Type, 2025
- Figure 5 : U.S. Market Shares for Biodefense-Related Rapid Pathogen Detection Devices, by Testing Method, 2025
- Figure 6 : U.S. Market Shares for Biodefense-Related Rapid Pathogen Detection Devices, by Device Type, 2025
- Figure 7 : U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by Application, 2025
- Figure 8 : U.S. Market Shares for Biodefense-Related Rapid Pathogen Identification and Treatments, by End User, 2025
- Figure 9 : Abbott: Revenue Shares, by Business Unit, FY 2025
- Figure 10 : Abbott: Revenue Shares, by Country/Region, FY 2025
- Figure 11 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2025
- Figure 12 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2025
- Figure 13 : BD: Revenue Shares, by Business Unit, FY 2025
- Figure 14 : BD: Revenue Shares, by Country/Region, FY 2025
- Figure 15 : Biomerieux: Revenue Shares, by Business Unit, FY 2025
- Figure 16 : Biomerieux: Revenue Shares, by Country/Region, FY 2025
- Figure 17 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2025
- Figure 18 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2025
- Figure 19 : Charles River Laboratories: Revenue Shares, by Business Unit, FY 2025
- Figure 20 : Charles River Laboratories: Revenue Shares, by Country/Region, FY 2025
- Figure 21 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2025
- Figure 22 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2025
- Figure 23 : Genscript: Revenue Shares, by Business Unit, FY 2025
- Figure 24 : Genscript: Revenue Shares, by Country/Region, FY 2025
- Figure 25 : GSK plc: Revenue Shares, by Business Unit, FY 2025
- Figure 26 : GSK plc: Revenue Shares, by Region/Country, FY 2025
- Figure 27 : Illumina Inc.: Revenue Shares, by Business Unit, FY 2025
- Figure 28 : Illumina Inc.: Revenue Shares, by Region, FY 2025
- Figure 29 : Johnson & Johnson: Revenue Shares, by Business Unit, FY 2025
- Figure 30 : Johnson & Johnson: Revenue Shares, by Country/Region, FY 2025
- Figure 31 : OraSure Technologies Inc.: Revenue Shares, by Business Unit, FY 2025
- Figure 32 : OraSure Technologies Inc.: Revenue Shares, by Country/ Region, FY 2025
- Figure 33 : Qiagen: Revenue Shares, by Business Unit, FY 2025
- Figure 34 : Qiagen: Revenue Shares, by Country/Region, FY 2025
- Figure 35 : Revvity: Revenue Shares, by Business Unit, FY 2025
- Figure 36 : Revvity: Revenue Shares, by Country/Region, FY 2025
- Figure 37 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2025
- Figure 38 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2025
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.